Fig. 11. Fate of fetal cells in vivo. (a) Transplanted cells in the peritoneal cavity or liver (lanes 2, 3) of immunodeficient mice with PCR probe identifying CMT1A human sequences. (b) In situ hybridization signals with human pancentromeric probe using FITC-conjugated anti-digoxigenin in human liver. (c) No hybridization signals with this probe were seen in mouse liver. (d) Histochemical staining of human liver for glycogen (pink color in cytoplasm) followed by in situ hybridization with human pancentromeric probe using peroxidase-conjugated anti-digoxigenin and development with diaminobenzidine (dark brown color in nuclei). (e,f) Transplanted fetal human cells (arrows) in the peritoneal cavity or liver (f) using human in situ hybridization probe. mc, microcarriers; Pa, portal area. (g) Immunostaining for human albumin in a transplanted cell (arrow) in the liver. (h-j) Transplanted cells (arrows) transduced with GFP lentiviral vector containing PGK, Alb or TTR promoters, with GFP immunostaining (green) and DAPI nuclear stain (blue). (k,l) Histochemical staining for glycogen (pink) followed by in situ hybridization using human pancentromeric probe to verify that lentiviral-vector-transduced cells (brown nuclear signals, arrows) were hepatocytes. (m-p) The same liver area verifying absence of fusion in lentiviral-vector-transduced human cells and native mouse cells with in situ hybridization using human plus mouse pancentromeric probes. A transplanted cell (arrow, m) hybridizes with the human probe. Hybridization signals with the mouse probe in cells other than the human cell (n), DAPI staining of nuclei (o) and merged view of m-o (p) to indicate that mouse signals were absent in the transplanted human cell and vice versa. Magnification: x400 (b-f, h-k); x600 (g,l, m-p).